These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34233965)

  • 1. Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.
    Francois B; Lambden S; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Grouin JM; Garaud JJ; Salcedo-Magguilli M; Levy M; Laterre PF
    BMJ Open; 2021 Jul; 11(7):e042921. PubMed ID: 34233965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
    François B; Lambden S; Fivez T; Gibot S; Derive M; Grouin JM; Salcedo-Magguilli M; Lemarié J; De Schryver N; Jalkanen V; Hicheur T; Garaud JJ; Cuvier V; Ferrer R; Bestle M; Pettilä V; Mira JP; Bouisse C; Mercier E; Vermassen J; Huberlant V; Vinatier I; Anguel N; Levy M; Laterre PF;
    Lancet Respir Med; 2023 Oct; 11(10):894-904. PubMed ID: 37269870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
    François B; Wittebole X; Ferrer R; Mira JP; Dugernier T; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Pickkers P; Vandenhende F; Garaud JJ; Sánchez M; Salcedo-Magguilli M; Laterre PF
    Intensive Care Med; 2020 Jul; 46(7):1425-1437. PubMed ID: 32468087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.
    François B; Lambden S; Garaud JJ; Derive M; Grouin JM; Asfar P; Darreau C; Mira JP; Quenot JP; Lemarié J; Mercier E; Lacherade JC; Vinsonneau C; Fivez T; Helms J; Badie J; Levy M; Cuvier V; Salcedo-Magguilli M; Laszlo-Pouvreau AL; Laterre PF; Gibot S;
    EClinicalMedicine; 2023 Jun; 60():102013. PubMed ID: 37350989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).
    Geven C; Blet A; Kox M; Hartmann O; Scigalla P; Zimmermann J; Marx G; Laterre PF; Mebazaa A; Pickkers P
    BMJ Open; 2019 Feb; 9(2):e024475. PubMed ID: 30782906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial.
    Legrand M; Oufella HA; De Backer D; Duranteau J; Leone M; Levy B; Rossignol P; Vicaut E; Dépret F;
    Trials; 2020 Jul; 21(1):601. PubMed ID: 32611377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies.
    Theobald V; Schmitt FCF; Middel CS; Gaissmaier L; Brenner T; Weigand MA
    Crit Care; 2024 Jan; 28(1):17. PubMed ID: 38191420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study into the reversal of septic shock with landiolol (beta blockade): STRESS-L Study protocol for a randomised trial.
    Lall R; Mistry D; Skilton E; Boota N; Regan S; Bion J; Gates S; Gordon AC; Lord J; McAuley DF; Perkins G; Singer M; Young D; Whitehouse T
    BMJ Open; 2021 Feb; 11(2):e043194. PubMed ID: 33593781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.
    Thomas-Rüddel D; Bauer M; Moita LF; Helbig C; Schlattmann P; Ehler J; Rahmel T; Meybohm P; Gründling M; Schenk H; Köcher T; Brunkhorst FM; Gräler M; Heger AJ; Weis S; ;
    BMJ Open; 2024 Apr; 14(4):e075158. PubMed ID: 38653508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
    Cuvier V; Lorch U; Witte S; Olivier A; Gibot S; Delor I; Garaud JJ; Derive M; Salcedo-Magguilli M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2270-2279. PubMed ID: 29885068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
    Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
    Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dynamic arterial elastance for weaning vasopressor support in septic shock patients: a randomised controlled trial protocol.
    Alvarado Sánchez JI; Montañez-Nariño AV; Cárdenas-Bolivar YR; Stozitzky-Ríos MV; Mora-Salamanca AF
    BMJ Open; 2024 Aug; 14(8):e086388. PubMed ID: 39117412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of iloprost in patients with septic shock-induced endotheliopathy-Protocol for the multicenter randomized, placebo-controlled, blinded, investigator-initiated trial.
    Bestle MH; Clausen NE; Søe-Jensen P; Kristiansen KT; Lange T; Johansson PI; Stensballe J; Perner A
    Acta Anaesthesiol Scand; 2020 May; 64(5):705-711. PubMed ID: 31950481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for fever control using external cooling in mechanically ventilated patients with septic shock: SEPSISCOOL II randomised controlled trial.
    Guénégou-Arnoux A; Murris J; Bechet S; Jung C; Auchabie J; Dupeyrat J; Anguel N; Asfar P; Badie J; Carpentier D; Chousterman B; Bourenne J; Delbove A; Devaquet J; Deye N; Dumas G; Dureau AF; Lascarrou JB; Legriel S; Guitton C; Jannière-Nartey C; Quenot JP; Lacherade JC; Maizel J; Mekontso Dessap A; Mourvillier B; Petua P; Plantefeve G; Richard JC; Robert A; Saccheri C; Vong LVP; Katsahian S; Schortgen F;
    BMJ Open; 2024 Jan; 14(1):e069430. PubMed ID: 38286691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P): Phase I/II clinical trial protocol of lipid emulsion therapy for stabilising cholesterol levels in sepsis and septic shock.
    Guirgis FW; Black LP; Rosenthal MD; Henson M; Ferreira J; Leeuwenburgh C; Kalynych C; Moldawer LL; Miller T; Jones L; Crandall M; Reddy ST; Wu SS; Moore FA
    BMJ Open; 2019 Sep; 9(9):e029348. PubMed ID: 31537565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality Reduction in Septic Shock by Plasma Adsorption (ROMPA): a protocol for a randomised clinical trial.
    Colomina-Climent F; Giménez-Esparza C; Portillo-Requena C; Allegue-Gallego JM; Galindo-Martínez M; Mollà-Jiménez C; Antón-Pascual JL; Rodríguez-Serra M; Martín-Ruíz JL; Fernández-Arroyo PJ; Blasco-Císcar EM; Cánovas-Robles J; Herrera-Murillo M; González-Hernández E; Sánchez-Morán F; Solera-Suárez M; Torres-Tortajada J; Nuñez-Martínez JM; Martín-Langerwerf D; Herrero-Gutiérrez E; Sebastián-Muñoz I; Palazón-Bru A; Gil-Guillén VF
    BMJ Open; 2016 Jul; 6(7):e011856. PubMed ID: 27406647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.